Abstract P4-05-24: A stroma-adjusted ZEB1 expression signature is associated with decreased immune cell infiltration and poor overall survival in breast cancer

Author(s):  
C James Block ◽  
Guojun Wu
2021 ◽  
Vol 11 ◽  
Author(s):  
Young-Sil An ◽  
Se-Hyuk Kim ◽  
Tae Hoon Roh ◽  
So Hyun Park ◽  
Tae-Gyu Kim ◽  
...  

BackgroundThe purpose of this study was to investigate the correlation between 18F-fluorodeoxyglucose (FDG) uptake and infiltrating immune cells in metastatic brain lesions.MethodsThis retrospective study included 34 patients with metastatic brain lesions who underwent brain 18F-FDG positron emission tomography (PET)/computed tomography (CT) followed by surgery. 18F-FDG uptake ratio was calculated by dividing the standardized uptake value (SUV) of the metastatic brain lesion by the contralateral normal white matter uptake value. We investigated the clinicopathological characteristics of the patients and analyzed the correlation between 18F-FDG uptake and infiltration of various immune cells. In addition, we evaluated immune-expression levels of glucose transporter 1 (GLUT1), hexokinase 2 (HK2), and Ki-67 in metastatic brain lesions.ResultsThe degree of 18F-FDG uptake of metastatic brain lesions was not significantly correlated with clinical parameters. There was no significant relationship between the 18F-FDG uptake and degree of immune cell infiltration in brain metastasis. Furthermore, other markers, such as GLUT1, HK2, and Ki-67, were not correlated with degree of 18F-FDG uptake. In metastatic brain lesions that originated from breast cancer, a higher degree of 18F-FDG uptake was observed in those with high expression of CD68.ConclusionsIn metastatic brain lesions, the degree of 18F-FDG uptake was not significantly associated with infiltration of immune cells. The 18F-FDG uptake of metastatic brain lesions from breast cancer, however, might be associated with macrophage activity.


2014 ◽  
Vol 63 (4) ◽  
pp. 395-406 ◽  
Author(s):  
Shenyou Sun ◽  
Xiaochun Fei ◽  
Yan Mao ◽  
Xiumin Wang ◽  
David H. Garfield ◽  
...  

2017 ◽  
Vol 28 ◽  
pp. i15
Author(s):  
J. Budczies ◽  
B.V. Sinn ◽  
B.M. Pfitzner ◽  
S. Villegas-Angel ◽  
B. Ingold-Heppner ◽  
...  

2021 ◽  
Author(s):  
Xiaoli Wang ◽  
Silu Xu ◽  
Lingli Huang ◽  
Lei Wang ◽  
Nan Wu

Abstract To identify molecular features related to immunogenic activity in breast cancer (BC) and provide new targets and directions for BC immunotherapy. We first used ESTIMATE to evaluate the degree of immune cell infiltration of the BC patients in TCGA and METABRIC, and explore the relationship between the degree of immune cell infiltration and prognosis of breast cancer patients. Then, we identified the cancer pathways, proteins, miRNAs related to BC immunogenicity, and predicted miRNAs target genes and identified the pathways related to target genes with KEGG pathway enrichment analysis. We also explored the correlation between PD-L1 expression level and cancer pathways and found that PD-L1 expression showed a positive association with cancer pathways. In this article we have successfully identified several cancer pathways, proteins, miRNAs and their target genes, which could be as promising new target for BC immunotherapy. And PD-L1 blockade therapy may be more effective in BC patients with the activation of some cancer pathways.


2022 ◽  
Vol 2022 ◽  
pp. 1-14
Author(s):  
Yuanyuan Feng ◽  
Xinfang Tang ◽  
Changcheng Li ◽  
Ying Su ◽  
Xiaoyu Wang ◽  
...  

Objective. ARID1A has been discovered as a potential cancer biomarker. But its role in hepatocellular carcinoma (HCC) is subject to considerable dispute. Methods. The relationship between ARID1A and clinical factors was investigated. Clinicopathological variables related to overall survival in HCC subjects were identified using Cox and Kaplan–Meier studies. The connection between immune infiltrating cells and ARID1A expression was investigated using the tumor Genome Atlas (TCGA) dataset for gene set enrichment analysis (GSEA). Finally, a cell experiment was used to confirm it. Results. The gender and cancer topography (T) categorization of HCC were linked to increased ARID1A expression. Participants with advanced levels of ARID1A expression had a worse prognosis than someone with lower levels. ARID1A was shown to be a risk indicator of overall survival on its own. ARID1A expression is inversely proportional to immune cell infiltration. In vitro, decreasing ARID1A expression substantially slowed the cell cycle and decreased HCC cell proliferation, migration, and invasion. Conclusion. The expression of ARID1A could be used to predict the outcome of HCC. It is closely related to tumor immune cell infiltration.


PLoS ONE ◽  
2018 ◽  
Vol 13 (10) ◽  
pp. e0204513 ◽  
Author(s):  
Kenichi Harano ◽  
Ying Wang ◽  
Bora Lim ◽  
Robert S. Seitz ◽  
Stephan W. Morris ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document